

Acute Lower Gastrointestinal Bleeding (LGIB): An Evidence-based Practical Approach

Alan Chuncharunee, M.D.

Division of Gastroenterology and Hepatolog<mark>y, De</mark>partment of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahid<mark>ol U</mark>niversity, Bangkok, Thailand

- Definition and etiologies of LGIB
- Clinical Assessment
- Management

Etiologies

Definition: Bleeding from a source distal to the ligament of Treitz (Mainly Colon, Rectum)

Common Etiologies

- Diverticular Bleeding
- Angioectasias
- Ischemic Colitis
- Neoplasms (Colon cancer, Polyps)
- Colitis (Inflammatory Bowel Disease, Infection, Radiation)



Resuscitation: IV crystalloids

History & Physical Examination:

- Bleeding: Pattern and amount
- Comorbidities(Cardiac, Renal), Prior GI Bleed, Medication(NSAIDs, Anti-Platelet, Anti-coagulant)
- Vital signs (Tachycardia, Orthostatic hypotension)
 Labs: CBC, Coagulation profile, Renal function
 Risk scores: Oakland Score, SHA2PE score

Clinical Assessment

Risk score

Low risk triage to discharge and treated as outpatient

- Oakland score ≤ 8
- SHA₂PE ≤ 1

Adverse outcomes prediction

- ABC score
- NOBLADS score
- Sengupta score
- Birmingham score
- Severe Acute LGIB(SALGIB) score

Clinical Assessment

Oakland score for predicting the safe discharge of patients presented with acute LGIB

Variables	Score	Variables	Score
Age(years)		SBP(mmHg)	
< 40 40-69 >70	0 1 2	50-89 90-119 120-129	5 4 3
Sex		130-159 >160	2 0
Female Male	0 1	Hemoglobin, g/dL	
Previous LGIB admission		36-69 70-89	22 17
No Yes	0 1	90-109 110-129	13 8
DRE		130-159	4
No blood Blood	0 1	>160	0

Oakland score ≤ 8: (ESGE2023, ACG2024, BSG2019)

Discharge and treated as Outpatient

Original Investigation | Gastroenterology and Hepatology External Validation of the Oakland Score to Assess Safe Hospital Discharge Among Adult Patients With Acute Lower Gastrointestinal Bleeding in the US

Kathryn Oakland, MD; Sandeepkumar Kothiwale, PhD; Tyler Forehand; Edmund Jackson, PhD; Cliff Bucknall, MD; Michael S. L. Sey, MD, MPH; Siddharth Singh, MD, MS Vipul Jairath, MD, PhD; Jonathan Perlin, MD

Table 3. Adverse Outcomes Among Patients With Low-Risk Oakland Scores

	Oakland Score, No. (%	6)	s ≤10 Points 38) (n = 6770)				
Outcome	≤8 Points (n = 3305) ≤9 Points (n = 4888) ≤10 Points (n = 6770) 132 (4.0) 236 (4.8) 383 (5.7) 11 (0.3) 16 (0.3) 21 (0.3) 0 0 0						
RBC transfusion	132 (4.0)	236 (4.8)	383 (5.7)				
Endoscopic hemostasis	11 (0.3)	16 (0.3)	21 (0.3)				
Mesenteric embolization	0	0	0				
Surgery	0	0	0				
In-hospital rebleeding	153 (4.6)	223 (4.6)	344 (5.1)				
In-hospital death	37 (1.1)	60 (1.2)	96 (1.4)				
Readmission with subsequent bleeding within 28 d	7 (0.2)	19 (0.4)	39 (0.6)				
Any adverse outcome	182 (5.5)	316 (6.5)	507 (7.5)				
Safe discharge sensitivity, %	98.4	97.5	96.0				
Safe discharge specificity, %	16.0	23.42	31.9				

Figure 1. Receiver Operating Characteristic Curve for Safe Discharge



Oakland score ≤ 8:

Safe discharge sensitivity 98.4% Identify population of 8.7% AUROC 0.87(Safe discharge)

Score 8-10

: No embolization and surgery needed

Medication management

Nonaspirin- NSAIDs

No benefit of changing NSAIDs to selective COX-2 inhibitors (Unlike UGIB !!)

Antiplatelets

Aspirin

ASA for Primary prevention: Consider Discontinuation

ASA for Secondary prevention: Generally, continue or reintroduce early

P2Y12 inhibitor

Hold temporarily in the case of severe bleeding

Multidisciplinary team approach (Cardiologist and Gastroenterologist) especially in the case with recent cardiac stent within 1 year

Should be resume within a maximum of 5 days

Medication management

Anticoagulants

Vitamin K Antagonists

- Generally hold, except for low risk patients
- In high thrombotic risk: LMWH should be considered at 48 hours
- In life-threatening LGIB and INR exceeding therapeutic range: Consider Reversal
- Reversal Agents:

4-factor prothrombin complex concentration, PCC: Factor II, VII, IX, X Vitamin K FFP

• For effective endoscopic hemostasis (INR should be less than or equal to 2.5)

Sengupta N, AJG,2024 Konstantinos T, Endoscopy, 2021

Medication management

Anticoagulants

DOAC (Direct Oral Anticoagulants)

- Generally hold, except for low risk patients
- Life-threatening LGIB and DOACs taken within the past 24 hours: Consider Reversal
- Agents: Idarucizumab for dabigatran

Andexanet alfa for apixaban and rivaroxaban

Transfusion management

Blood transfusion:

Restrictive strategies (Hemodynamically stable with no history of CVD) Threshold Hb ≤ 7 g/dl, with target of post-transfusion at 7-9 g/dl

More liberal strategy (Hemodynamically stable with known CVD) Threshold Hb ≤ 8 g/dl, with target of post-transfusion at 10 g/dl

Platelet transfusion:

Severe LGIB keep Platelet count > $30x \ 10^9$ /L and higher threshold of > $50 \ x 10^9$ /L in case with planned endoscopic procedures

Antifibrinolytics (Tranexamic acid): No significant benefit

CT Angiography VS Colonoscopy

CT Angiography

When to perform CTA

 Severe, ongoing bleeding, hemodynamic instability

Shock index (Heart rate / Systolic BP) > 1

- Rapid test, no bowel prep needed
- If extravasation found Possible Embolization by Interventional Radiologist



CT Angiography

Factor associated with Positive CTA

- Within 4 hours of hematochezia
- Shock index > 1
- Recent bowel resection or endoscopic intervention
- Transfusion of 3 unit of PRBC per day
- Use of Antiplatelet



Oakland K, Gut 2019 Sengupta N, AJG,2024

Colonoscopy

When to use colonoscopy

- Stable or slowed bleeding
- Highest yield after adequate bowel prep
- Therapeutic potential: Clipping, banding, APC
- Timing: Within 24-72 hours is acceptable , No mortality benefit to < 24 hours



Urgent vs Standard Colonoscopy



D	Urgent		nt	Standard Risk Ratio		Risk Ratio					
	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% CI		
	Green 2005	7	50	6	50	82.2%	1.17 [0.42, 3.23]	2005	-		
	Laine 2010	0	36	2	36	9.4%	0.20 [0.01, 4.03]	2010 +			
	Van Rongen 2018	0	63	1	69	8.4%	0.36 [0.02, 8.79]	2018 -			
	Total (95% CI)		149		155	100.0%	0.90 [0.36, 2.25]				
	Total events	7		9							
	Heterogeneity: Tau ² =	: 0.00; Ch	² = 1.5	7. df = 2 ((P = 0.4)	6); I [#] = 09	6		1		-
	Test for overall effect	Z=0.23	(P = 0.8)	32)				0.01	0.1	1 10	10
						Si	urgery		Urgent Colonoscopy	Standard Colonoscopy	
E		Urge	nt	Stand	ard		Risk Ratio		Risk Ratio		
-	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% CI		
	Green 2005	1	50	0	50	47.2%	3.00 [0.13, 71.92]	2005			
	Laine 2010	2	36	0	36	52.8%	5.00 [0.25, 100.63]	2010		-	
	Van Rongen 2018	0	63	0	69		Not estimable	2018			
	Total (95% CI)		149		155	100.0%	3.93 [0.44, 34.83]				
	Total events	3		0							
	Heterogeneity: Tau ^a = 0.00; Chi ^a = 0.05, df = 1 (P = 0.82); P = 0%						+		H H H	+	
	Test for overall effect	Z=1.23	(P = 0.2)	22)				0.005	0.1	1 10	200
						- IV	iortality		Lizzant Colonoscony	Standard Calanascony	

FIGURE 2. Random effects meta-analysis comparing the difference in patient outcomes for urgent versus standard colonoscopy in acute lower gastrointestinal bleeding. A, Length of stay, (B) units of blood transfused, (C) rate of patients requiring additional intervention, (D) rate of patients requiring surgery, and (E) mortality. Matterial bleeding

No different in outcomes

Colonoscopy:

- Carefully inspection during insertion and withdrawal including terminal ileal intubation
- Clear cap assisted
- In patient with high quality colonoscopy within 12 months showing diverticulosis and bleeding subsided: No colonoscopy needed
- 4-6 L of PEG over 3-4 hours (Alternatively, Split-dose and/or the use of 1 L low-vol prep)
- Unprepared evaluation or routine flexible sigmoidoscopy: NOT RECOMMENDED

Diverticular bleeding



Combined adrenaline injection with contact thermal coagulation



Endoscopic clipping



Endoscopic ligation





Endoscopic detachable snare



Hemostatic topical agents

Angioectasia



Argon plasma coagulation (APC)

Management Flow

LGIB

Bleeding severity assessment Clinical judgement (History and Physical Exam

Hemodynamically unstable Resuscitation

Diagnosis

CTA

UGI endoscopy unless bleeding site identified by CTA Reserve emergency laparotomy in failed endoscopy and radiology

Treatment

Transcatheter embolization within 60 mins Surgery if failed endoscopic or radiologic treatment

Management Flow

LGIB

Bleeding severity assessment Clinical judgement (History and Physical Exam)

Hemodynamically unstable Resuscitation

Diagnosis

CTA

UGI endoscopy unless bleeding site identified by CTA Reserve emergency laparotomy in failed endoscopy and radiology

Treatment

Transcatheter embolization within 60 mins Surgery if failed endoscopic or radiologic treatment Hemodynamically stable

Safe discharge and outpatient treatment if OAKLAND score ≤ 8

Diagnosis

Colonoscopy Adequate bowel prep 4-6 L

Treatment

Diverticular bleeding: TTS/Cap-mounted clip, EBL Angioectasia: APC

Delayed post-polypectomy bleeding

- Mechanical therapy (TTS/cap-mounted clip or EBL)
- Contact thermal treatment

Thank you for your attention

